Lindbrook Capital, LLC Vanda Pharmaceuticals Inc. Transaction History

Lindbrook Capital, LLC

$1.06 Billion
Q2 2024

A detailed history of Lindbrook Capital, LLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 73 shares of VNDA stock, worth $340. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$340

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$3.91 - $6.5 $285 - $474	73 New	73 $0
Q2 2023 Jul 28, 2023	BUY	$5.9 - $6.95 $3,309 - $3,898	561 Added 500.89%	673 $4,000
Q1 2023 Apr 26, 2023	SELL	$6.18 - $7.99 $2,706 - $3,499	-438 Reduced 79.64%	112 $0
Q4 2022 Jan 24, 2023	SELL	$6.87 - $10.96 $659 - $1,052	-96 Reduced 14.86%	550 $0
Q3 2022 Nov 10, 2022	SELL	$9.44 - $11.76 $6,777 - $8,443	-718 Reduced 52.64%	646 $6,000
Q2 2022 Aug 01, 2022	BUY	$9.31 - $11.84 $6,395 - $8,134	687 Added 101.48%	1,364 $15,000
Q1 2022 Apr 21, 2022	BUY	$10.84 - $16.55 $336 - $513	31 Added 4.8%	677 $8,000
Q3 2020 Nov 03, 2020	BUY	$9.32 - $12.02 $894 - $1,153	96 Added 17.45%	646 $6,000
Q1 2020 Apr 22, 2020	BUY	$7.5 - $16.8 $4,125 - $9,240	550 New	550 $6,000

Others Institutions Holding VNDA

# of Institutions

156

Shares Held

45.1M

Call Options Held

136K

Put Options Held

220K

Black Rock Inc. New York, NY

8.14M
Shares

$38 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

4.11M
Shares

$19.2 Million
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

3.43M
Shares

$16 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

2.15M
Shares

$10.1 Million
1.49% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.01M
Shares

$9.4 Million
0.0% of portfolio

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $264M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account